Tango Therapeutics(TNGX) - 2025 Q2 - Quarterly Results

Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights – First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors – – First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5 inhibitor in development for glioblastoma – BOSTON, August 5, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next gener ...